The upgrade of Passage Bio to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

Passage Bio, Inc. (NASDAQ:PASG – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for shares of Passage Bio in a research report ...

PASG stock opened at $0.47 on Tuesday. Passage Bio has a 52-week low of $0.38 and a 52-week high of $1.79. The firm has a market cap of $29.04 million, a P/E ratio of -0.40 and a beta of 1.55. The ...

Equities researchers at Wedbush issued their FY2029 EPS estimates for Passage Bio in a research note issued to investors on Tuesday, March 4th. Wedbush analyst Y. Zhong forecasts that the company will ...

Passage Bio (NASDAQ:PASG – Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.21 ...

PASSAGE BIO, INC. earnings at a glance (GAAP ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

The company was founded in 2017 and is headquartered in Stamford, Connecticut. Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.

A replay of the presentation will be available for 30 days following the event. Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of ...